BAX Baxter International
FY2025 10-K
Baxter International (BAX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: diversified healthcare products including IV solutions, infusion systems, parenteral nutrition, surgical and respiratory devices
- • New segment structure: three reportable segments as of Q3 2023 — Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals
Management Discussion & Analysis
- • Kidney Care business sold for $3.80B cash, net after-tax proceeds approx. $3.3B completed Jan 31, 2025
- • Legacy indebtedness of $3.81B repaid in 2025, excluding $2.00B repaid from new notes offering
Risk Factors
- • FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations
- • Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified
Financial SummaryXBRL
Revenue
$11.2B
Net Income
-$957M
Gross Margin
30.1%
Operating Margin
-2.7%
Net Margin
-8.5%
ROE
-15.6%
Total Assets
$20.1B
EPS (Diluted)
$-1.87
Operating Cash Flow
$845M
Source: XBRL data from Baxter International FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Baxter International
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.